UniSuper Management Pty Ltd Has $1.99 Million Holdings in Align Technology, Inc. (NASDAQ:ALGN)

UniSuper Management Pty Ltd grew its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 23.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,543 shares of the medical equipment provider’s stock after buying an additional 1,817 shares during the period. UniSuper Management Pty Ltd’s holdings in Align Technology were worth $1,990,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Picton Mahoney Asset Management increased its position in Align Technology by 69.9% in the 4th quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Align Technology by 9.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 766 shares of the medical equipment provider’s stock valued at $158,000 after acquiring an additional 64 shares during the period. Beech Hill Advisors Inc. increased its holdings in shares of Align Technology by 0.6% during the fourth quarter. Beech Hill Advisors Inc. now owns 11,632 shares of the medical equipment provider’s stock valued at $2,425,000 after acquiring an additional 65 shares in the last quarter. New York Life Investment Management LLC raised its position in shares of Align Technology by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 9,406 shares of the medical equipment provider’s stock worth $1,961,000 after purchasing an additional 68 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Align Technology by 1.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,799 shares of the medical equipment provider’s stock worth $1,626,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Price Performance

NASDAQ ALGN opened at $159.21 on Monday. The business’s fifty day moving average is $193.72 and its 200-day moving average is $214.48. The stock has a market capitalization of $11.72 billion, a price-to-earnings ratio of 28.38, a PEG ratio of 2.24 and a beta of 1.69. Align Technology, Inc. has a one year low of $157.57 and a one year high of $331.64.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 EPS for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a return on equity of 13.84% and a net margin of 10.54%. Research analysts expect that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALGN. Wells Fargo & Company started coverage on shares of Align Technology in a research note on Friday, February 14th. They set an “overweight” rating and a $255.00 price target for the company. Leerink Partners upgraded shares of Align Technology from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $235.00 to $280.00 in a report on Monday, January 6th. Evercore ISI lifted their price target on Align Technology from $240.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Jefferies Financial Group decreased their price objective on Align Technology from $285.00 to $260.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partnrs upgraded Align Technology from a “hold” rating to a “strong-buy” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Align Technology presently has a consensus rating of “Moderate Buy” and a consensus target price of $262.64.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.